Mark Yan
Impact in
-
- Lymphoma Diagnosis and Treatment
-
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- Lymphoma Diagnosis and Treatment 8
-
- Acute Myeloid Leukemia Research 4
- Co-authors
- Calvin Lee (3 shared papers)Jamie H. Hirata (3 shared papers)Franck Morschhauser (2 shared papers)Hervé Tilly (3 shared papers)Andy I. Chen (1 shared paper)Nancy L. Bartlett (1 shared paper)Gilles Salles (2 shared papers)Jeff Porter Sharman (1 shared paper)
- Journals
- Blood (5 papers)Journal of Clinical Oncology (2 papers)Blood Advances (2 papers)The Lancet Oncology (1 paper)Nature Medicine (1 paper)
- Partner nations
- CanadaUnited StatesSwitzerland
In The Last Decade
Mark Yan
13 papers receiving 323 citations
Peers
Comparison fields: 5 of 32
- Pathology and Forensic Medicine 87
- Oncology 102
- Cancer Research 59
- Pulmonary and Respiratory Medicine 56
- Hematology 22
Countries citing papers authored by Mark Yan
This map shows the geographic impact of Mark Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yan more than expected).
Fields of papers citing papers by Mark Yan
This network shows the impact of papers produced by Mark Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yan. The network helps show where Mark Yan may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Yan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 110 | |
| 2 | 2022 | 94 | |
| 3 | 2021 | 55 | |
| 4 | 2021 | 23 | |
| 5 | 2025 | 13 | |
| 6 | 2022 | 9 | |
| 7 | 2021 | 6 | |
| 8 | 2022 | 5 | |
| 9 | 2022 | 5 | |
| 10 | 2024 | 5 | |
| 11 | 2020 | 2 | |
| 12 | 2025 | 2 | |
| 13 | 2017 | 1 | |
| 14 | 2025 | 0 | |
| 15 | 2026 | 0 | |
| 16 | 2026 | 0 |
About Mark Yan
Mark Yan is a scholar working on Pathology and Forensic Medicine, Hematology, Oncology, Pulmonary and Respiratory Medicine and Statistics and Probability, having authored 16 papers that have together received 330 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (8 papers), Acute Myeloid Leukemia Research (4 papers), Lung Cancer Treatments and Mutations (2 papers), Cancer survivorship and care (2 papers), Cancer Treatment and Pharmacology (1 paper), Statistical Methods in Clinical Trials (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (87 citations), Oncology (102 citations), Cancer Research (59 citations), Pulmonary and Respiratory Medicine (56 citations) and Hematology (22 citations). Mark Yan has collaborated with scholars based in Canada, United States and Switzerland. Frequent co-authors include Calvin Lee, Jamie H. Hirata, Franck Morschhauser, Hervé Tilly, Andy I. Chen, Nancy L. Bartlett, Gilles Salles, Jeff Porter Sharman, Dan Lü and Javier L Munoz. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, The Lancet Oncology and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.